Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants
PDY17892
Phase 1 other active
Quick answer
Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants for Immune system diseases is a Phase 1 program (other) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Immune system diseases
- Phase
- Phase 1
- Modality
- other
- Status
- active